prostatic neoplasms/nausea

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 39 rezilta yo

Cooperative clinical trials of the National Prostatic Cancer Project: Protocol 900.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In May 1978, the National Prostatic Cancer Project Treatment Subgroup activated its first clinical trial evaluating adjuvant chemotherapy (Protocol 900). This protocol is a comparison of long-term adjuvant chemotherapy with cyclophosphamide, estramustine phosphate, or no additional treatment in

[Clinical effect of UFT on prostatic cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A phase II study of UFT, a mixture of futraful and uracil in a rate of 1:4, was performed for prostatic cancer in 5 cooperative institutions. UFT was orally administered at a daily dose of 600 mg (t.i.d.) for 4 weeks. Twenty-two patients treated with UFT were evaluated according to Koyama-Saito's

[Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A phase I study of orally administered flutamide (a pure anti-androgen) was performed in 26 patients with prostatic cancer. No side effects were observed in 11 patients receiving single doses of either 125, 250, 375 or 500 mg. However, in the daily dosing schedule of 375, 750, 1125 and 1,500 mg/day

Antiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The antiemetic effect of prednisolone on nausea/vomiting was investigated in 67 patients with advanced prostatic cancer and a performance status of < or = 2. The study was a double-blind, placebo-controlled, randomized trial with a parallel group design. The objective was to compare the incidence

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The therapeutic efficacy and safety of various doses of leuprorelin acetate depot were determined in an open, multicentre study of patients with locally advanced or metastatic prostatic cancer (stages C, D1 or D2). Patients were randomly assigned to receive 3.75 mg (30 cases), 7.5 mg (eight cases),

[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with

Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Both alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) inhibit sequential enzymatic reactions in the pathway of polyamine biosynthesis. Since polyamines may be important factors in proliferation of cancer cells and DFMO combined with MGBG has shown synergistic

[A trial of combination chemotherapy. Cis-platinum, peplomycin and adriamycin for advanced prostatic cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Between September 1982 and May 1984, combination chemotherapy with cis-platinum, peplomycin and adriamycin was administered to 12 patients with histologically confirmed adenocarcinoma of the prostate and progressive disease with evaluable parameters. Cis-platinum (CDDP) 20 mg/sqm was administered

[Chemoendocrine therapy of newly diagnosed advanced prostatic cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

From November 1981 to November 1987, 35 patients with newly diagnosed advanced prostatic cancer (6 Stage C cases and 29 Stage D2 cases) were treated by chemoendocrine therapy consisting of orchiectomy, diethylstilbestrol-diphosphate and cisplatin. Objective responses were assessed at 3 months after

Combination treatment versus LHRH alone in advanced prostatic cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Androgen deprivation based on hormone manipulation is the treatment of choice in advanced prostatic cancer. The unequivocal role of adrenal androgens in the growth of prostatic cancer after medical or surgical castration requires a new logical approach (complete androgen blockade) in the treatment

Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A multicenter cooperative study was conducted to evaluate the clinical efficacy and safety of cis-diammine(glycolato)platinum (254-S), a second-generation anticancer platinum complex, in the treatment of genitourinary cancers. 254-S was given i.v. at 100 mg/m2 at 4-week intervals. As a result, 2

[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog. Preliminary studies performed in our hospitals demonstrate the releasing effect of Ifosfamide for persistent pain caused by metastases of the prostatic cancer at various regions. Ifosfamide was given 2 grams

[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12

Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The activity of the pure non-steroidal antiandrogen nilutamide as a single agent was evaluated in 44 patients with metastatic carcinoma of the prostate. Objective (partial) response rates (95% confidence limits) were 38.5 (18.7)% in 26 previously untreated patients and 5.5 (11%) in 18 patients

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen nilutamide as a single agent. Objective response rate was 38.5 +/- 18.7% (95% confidence interval). Median progression-free survival and median survival were 9 and 23

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye